BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 28039034)

  • 1. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer.
    El Hadi H; Abdellaoui-Maane I; Kottwitz D; El Amrani M; Bouchoutrouch N; Qmichou Z; Karkouri M; ElAttar H; Errihani H; Fernandez PL; Bakri Y; Sefrioui H; Moumen A
    Gene; 2017 Mar; 605():114-122. PubMed ID: 28039034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
    Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
    Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Usefulness of a One-Tube Nested Reverse Transcription Quantitative Polymerase Chain Reaction Assay for Evaluating Human Epidermal Growth Factor Receptor 2 mRNA Overexpression in Formalin-Fixed and Paraffin-Embedded Breast Cancer Tissue Samples.
    Wang HY; Ahn S; Park S; Kim S; Lee H
    Pathobiology; 2017; 84(2):57-70. PubMed ID: 27544315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples.
    Pu T; Guo P; Qiu Y; Chen S; Yang L; Sun L; Ye F; Bu H
    Int J Clin Exp Pathol; 2015; 8(9):10565-74. PubMed ID: 26617766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples.
    Wang HY; Kim S; Park S; Kim S; Jung D; Park KH; Lee H
    Exp Mol Pathol; 2014 Dec; 97(3):368-74. PubMed ID: 25236569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
    BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence.
    Wasserman BE; Carvajal-Hausdorf DE; Ho K; Wong W; Wu N; Chu VC; Lai EW; Weidler JM; Bates M; Neumeister V; Rimm DL
    Lab Invest; 2017 Dec; 97(12):1521-1526. PubMed ID: 28892092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
    Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
    J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divisional role of quantitative HER2 testing in breast cancer.
    Yamamoto-Ibusuki M; Yamamoto Y; Fu P; Yamamoto S; Fujiwara S; Honda Y; Iyama K; Iwase H
    Breast Cancer; 2015 Mar; 22(2):161-71. PubMed ID: 23604955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings.
    Gheni N; Westenberg D
    Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S123-S128. PubMed ID: 32108644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Droplet Digitalâ„¢ PCR quantitation of HER2 expression in FFPE breast cancer samples.
    Heredia NJ; Belgrader P; Wang S; Koehler R; Regan J; Cosman AM; Saxonov S; Hindson B; Tanner SC; Brown AS; Karlin-Neumann G
    Methods; 2013 Jan; 59(1):S20-3. PubMed ID: 23036330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.
    Gupta S; Mani NR; Carvajal-Hausdorf DE; Bossuyt V; Ho K; Weidler J; Wong W; Rhees B; Bates M; Rimm DL
    Lab Invest; 2018 Aug; 98(8):1076-1083. PubMed ID: 29858579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
    Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
    J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
    Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of HER2 amplification in formalin-fixed paraffin-embedded breast carcinoma tissue with digital PCR using two TFF3 sequences as internal reference.
    Yu R; Xuan W; Zhou L; Luo Y; Liu X; Xiong P; Ren X
    Exp Mol Pathol; 2018 Jun; 104(3):235-238. PubMed ID: 29715436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
    Lung J; Lin YC; Hung MS; Jiang YY; Lee KD; Lin PY; Tsai YH
    Lung Cancer; 2016 Apr; 94():114-20. PubMed ID: 26973216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Human Epidermal Growth Factor Receptor 2 (HER2) Gene Status in Human Breast Cancer Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens by Fluorescence In Situ Hybridization (FISH).
    Hwang HC; Gown AM
    Methods Mol Biol; 2016; 1406():61-70. PubMed ID: 26820945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.